Comparative efficacy of Surufatinib plus transarterial embolization versus Surufatinib monotherapy in neuroendocrine tumor with liver metastasis: A prospective, randomised, controlled trial

#3956

Introduction: Surufatinib (SUR), an oral tyrosine kinase inhibitor, is a standard treatment for advanced NETs. Transarterial embolization (TAE) is a key local treatment for inoperable liver metastases from NETs.

Aim(s): To evaluate the efficacy and safety of combining SUR with TAE compared to SUR alone in patients with hepatic metastases from NETs.

Materials and methods: In this trial, patients≥18 years with Grade 1 or 2 liver metastatic NETs, measurable lesions (RECIST 1.1), and ECOG 0-2 were enrolled. Randomized 1:1, they received SUR (300 mg daily) plus TAE or SUR alone. The primary endpoint was progression-free survival (PFS), with secondary endpoints including objective response rate (ORR), intrahepatic response rate (iHRR), disease control rate (DCR), overall survival (OS), and adverse event incidence.

Conference:

Presenting Author:

Authors: Li X, Li R, Cheng K, Cao D,

Keywords: Surufatinib, transarterial embolization, neuroendocrine tumor, liver metastasis,